European Journal of Cancer
Volume 41, Issue 18 , Pages 2853-2860, December 2005

Differential sensitivity of liposarcoma subtypes to chemotherapy

Sarcoma Unit, Department of Medicine, Royal Marsden Hospital, Fulham Road, London SW3 6JJ, UK

Received 19 May 2005; received in revised form 7 July 2005; accepted 7 July 2005.

Abstract 

Liposarcoma is one of the most common soft tissue sarcomas and has a number of different subtypes: well-differentiated; dedifferentiated; myxoid/round cell; and pleomorphic. However, the response of these subgroups to chemotherapy is not well documented. In this study, we have conducted a retrospective analysis of a prospectively maintained database of soft tissue sarcoma patients treated at the Royal Marsden Hospital. Eighty-eight liposarcoma patients who received chemotherapy between August 1989 and June 2004 were identified. The response rates to chemotherapy of the different histological subtypes and overall and progression free survival were investigated. Survival according to histological grade was also assessed. A statistically significant higher response rate to first-line chemotherapy was observed in patients with myxoid liposarcoma compared to de- and well-differentiated tumours, 48% (95%CI; 28–69) and 11% (95%CI; 2–29), P=0.005. Similarly, those with myxoid liposarcoma had a significantly higher response rate compared to all other liposarcoma patients, 48% (95%CI; 28–69) and 18% (95%CI; 8–31). Patients with lower grade tumours had better overall survival. This retrospective analysis suggests that myxoid liposarcoma is relatively chemosensitive in comparison to a combination of other liposarcomas, and in particular de- and well-differentiated tumours. Further confirmation of these results should be sought by similar analyses of other databases.

Keywords: Liposarcoma, Histological subtype, Chemotherapy, Response rate, Differential sensitivity, Myxoid liposarcoma

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

PII: S0959-8049(05)00796-3

doi:10.1016/j.ejca.2005.07.023

European Journal of Cancer
Volume 41, Issue 18 , Pages 2853-2860, December 2005